Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer — TAME-01  

Locally Advanced HER2-negative Breast Cancer Clinical Trial

Official title: Phase II Feasibility Study of Weekly Paclitaxel Followed by Weekly Doxorubicin Plus Daily Oral Cyclophosphamide for Locally Advanced HER2-Negative Breast Cancer

Status Terminated

Clinical Trial Summary

The purpose of this study is to determine whether weekly paclitaxel followed by weekly doxorubicin plus daily oral cyclophosphamide without granulocyte colony-stimulating factor (G-CSF) is feasible in the treatment of locally advanced HER2-negative breast cancer.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Neoplasms
• Locally Advanced HER2-negative Breast Cancer

• NCT number: NCT01329627
• Study type: Interventional
• Source: Instituto do Cancer do Estado de São Paulo
• Status: Terminated
• Phase: Phase 2
• Start date: August 2010
• Completion date: August 2012